Omar Farouk
Director, SmartFuel
⭐⭐⭐⭐☆
“Partnering boosted fuel sales at targeted sites — and helped support frontline staff.”
Discover a world of products and services at a special discount for the NHS.
Providing a digital newsfeed to the NHS along with discounts from UK businesses, we provide a way to offer NHS workers a directory of businesses willing to show their appreciation of the NHS.
In a major win for women’s health, the NHS has approved the daily use of linzagolix, a groundbreaking oral medication that offers new hope to those living with endometriosis—a chronic and often debilitating condition that affects 1 in 10 women of reproductive age in the UK.
The approval of this drug provides a non-surgical treatment option for a condition that has long been under-recognised, underdiagnosed, and underfunded.
Endometriosis occurs when tissue similar to the lining of the womb begins to grow outside the uterus, most commonly affecting the ovaries, fallopian tubes, and the pelvic lining. This can lead to severe pelvic pain, fatigue, digestive issues, and infertility—with symptoms often intensifying around menstruation.
Despite its prevalence, many women experience a delay of seven years or more before receiving a diagnosis, leaving them to suffer in silence with little support or treatment.
Until now, the main treatment options have been painkillers, hormone therapy, or invasive surgery such as laparoscopy or hysterectomy—each with their own limitations and risks.
Linzagolix is part of a new class of medicines called oral GnRH antagonists, which work by suppressing the production of oestrogen and other sex hormones that drive the growth of endometrial-like tissue. Unlike older hormone therapies, linzagolix allows for precise dose control, which can be tailored to each patient’s needs and tolerability.
By reducing hormone levels, the drug alleviates chronic pelvic pain, heavy menstrual bleeding, and inflammation, all while offering the convenience of once-daily oral dosing—a significant improvement over injectable alternatives.
Clinical trials have shown linzagolix to be both effective and well-tolerated, with many women reporting a substantial improvement in quality of life.
Now officially approved for use on the NHS, linzagolix is expected to benefit over 1,000 women per year, initially targeting those with moderate to severe symptoms who have not responded to other treatments.
Healthcare professionals hope this will reduce the need for repeated surgeries, ease pressure on gynaecology services, and most importantly, give patients greater control over their condition.
Dr. Samantha Hall, a consultant gynaecologist, welcomed the approval:
“Linzagolix offers an empowering option for women who are desperate for relief but wish to avoid surgery or harsh hormonal side effects. It marks a new era in how we treat and talk about endometriosis.”
The NHS’s decision to fund linzagolix forms part of a broader effort to improve outcomes for women’s health, including greater investment in menstrual health research, faster diagnosis times, and improved training for healthcare professionals.
In 2022, the UK Government launched its first-ever Women’s Health Strategy, acknowledging long-standing gender health inequalities and vowing to improve access to care. The addition of linzagolix to the NHS formulary is a concrete step forward in delivering on that promise.
While the approval of linzagolix won’t be a cure for all, it represents real progress in a field where options have historically been limited. Patient advocacy groups, including Endometriosis UK, have praised the move and are continuing to campaign for better awareness, earlier intervention, and expanded access to innovative treatments.
In the words of one patient:
“It’s not just a pill. It’s freedom, it’s sleep, it’s being able to go to work without fear of collapsing in pain.”
As awareness of endometriosis grows and access to effective treatment improves, linzagolix may well become a lifeline for thousands—helping women reclaim their health, dignity, and daily lives.
Real reviews from happy clients
“Partnering boosted fuel sales at targeted sites — and helped support frontline staff.”
“Our cleaning service gained loyal NHS clients through this platform.”
“I’ve saved hundreds on essentials and days out. It’s a genuine thank-you that makes a difference.”
“The scheme matches our values — helping NHS workers while increasing brand visibility.”
“Signed up in minutes and had a holiday booked the same week — at a price I could afford.”
“The tech discount saved me £300 on a new laptop — perfect for my CPD studies.”
“Nice to know businesses value what we do. The savings really help during tough months.”
“All the codes worked without hassle — no gimmicks, just proper deals.”
“Great selection of brands that actually understand our work schedules.”
“It’s rewarding to give back — and sales from NHS staff are steadily growing.”
“Groceries, uniforms, and even fuel — all cheaper through Healthcare Discounts.”
“Plenty of sportswear and fitness offers — exactly what I was looking for.”
“NHS bookings filled our off-peak rooms — fantastic partnership ROI.”
“I recommend it to every new starter — sign up and you’re saving within hours.”
“The platform builds loyalty — NHS staff keep coming back to our brand.”
“The travel savings helped me attend a medical conference without breaking the bank.”
“We’ve seen a 30% increase in NHS customers since listing our offer here.”
“The discounts on everyday shopping make a genuine difference to my budget.”
“Partnering with Healthcare Discounts has connected us directly with an engaged NHS audience.”
“No hoops to jump through — easy sign-up and instant benefits.”
“Fantastic exposure for our brand and a chance to say thanks to key workers.”
“Our NHS dining discount is a hit — table bookings have gone up 20%.”
